Hangzhou Tigermed Consulting (300347.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Life Sciences Tools & Services · China · ISIN CNE100001KV8
Hangzhou Tigermed Consulting financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 6.60 bn CNY | 6.83 bn CNY |
| Gross profit | 2.24 bn CNY | 1.87 bn CNY |
| Operating income | 664.42 m CNY | 666.64 m CNY |
| EBIT | 810.77 m CNY | 1.09 bn CNY |
| Net income | 405.14 m CNY | 887.89 m CNY |
| Diluted EPS – continuing operations | 0.47 CNY | 1.03 CNY |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
More stocks
- CHEMED CORP (CHE)
- Allfunds Group PLC (ALLFG.AS)
- Nkt A/S (NKT.CO)
- Oberbank AG (OBS.VI)
- Victory Capital Holdings, Inc. (VCTR)
- Pls Group Ltd (PLS.AX)
- APPLIED OPTOELECTRONICS, INC. (AAOI)
- Haidilao International Holding Ltd (6862.HK)
- Rumo S.A (RAIL3.SA)
- Transocean Ltd. (RIG)
- QUALYS, INC. (QLYS)
- Brunello Cucinelli SpA (BC.MI)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.